Literature DB >> 11985831

The peroxisome proliferator-activated receptor alpha-selective activator ciprofibrate upregulates expression of genes encoding fatty acid oxidation and ketogenesis enzymes in rat brain.

Tim E Cullingford1, Colin T Dolphin, Hitoshi Sato.   

Abstract

Activated peroxisome proliferator activated receptor alpha (PPAR alpha) protects against the cellular inflammatory response, and is central to fatty acid-mediated upregulation of the gene encoding the key ketogenic enzyme mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase (mHS). We have previously demonstrated both PPAR alpha and mHS expression in brain, implying that brain-targeted PPAR alpha activators may likewise up-regulate mHS expression in brain. Thus, to attempt pharmacological activation of brain PPAR alpha in vivo, we have administered to rats two drugs with previously defined actions in rat brain, namely the PPAR alpha-selective activator ciprofibrate and the pan-PPAR activator valproate. Using the sensitive and discriminatory RNase protection co-assay, we demonstrate that both ciprofibrate and valproate induce mHS expression in liver, the archetypal PPAR alpha-expressing organ. Furthermore, ciprofibrate potently increases mHS mRNA abundance in rat brain, together with lesser increases in two other PPAR alpha-regulated mRNAs. Thus we demonstrate, for the first time, up-regulation of expression of PPAR alpha-dependent genes including mHS in brain, with implications in the increased elimination of neuro-inflammatory lipids and concomitant increased production of neuro-protective ketone bodies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11985831     DOI: 10.1016/s0028-3908(02)00014-x

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  17 in total

1.  Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder.

Authors:  Richard P Bazinet; Margaret T Weis; Stanley I Rapoport; Thad A Rosenberger
Journal:  Psychopharmacology (Berl)       Date:  2005-12-13       Impact factor: 4.530

Review 2.  Ketogenic diets, mitochondria, and neurological diseases.

Authors:  Lindsey B Gano; Manisha Patel; Jong M Rho
Journal:  J Lipid Res       Date:  2014-05-20       Impact factor: 5.922

Review 3.  Metabolic and Inflammatory Adaptation of Reactive Astrocytes: Role of PPARs.

Authors:  José Iglesias; Ludis Morales; George E Barreto
Journal:  Mol Neurobiol       Date:  2016-03-17       Impact factor: 5.590

Review 4.  Peroxisome proliferator activated receptor α ligands as anticancer drugs targeting mitochondrial metabolism.

Authors:  Maja Grabacka; Malgorzata Pierzchalska; Krzysztof Reiss
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

5.  Valproyl-CoA and esterified valproic acid are not found in brains of rats treated with valproic acid, but the brain concentrations of CoA and acetyl-CoA are altered.

Authors:  Joseph Deutsch; Stanley I Rapoport; Thad A Rosenberger
Journal:  Neurochem Res       Date:  2003-06       Impact factor: 3.996

6.  PPARγ Agonists Attenuate Trigeminal Neuropathic Pain.

Authors:  Danielle N Lyons; Liping Zhang; Robert J Danaher; Craig S Miller; Karin N Westlund
Journal:  Clin J Pain       Date:  2017-12       Impact factor: 3.442

7.  Adenosine, ketogenic diet and epilepsy: the emerging therapeutic relationship between metabolism and brain activity.

Authors:  S A Masino; M Kawamura; C D Wasser; C A Wasser; L T Pomeroy; D N Ruskin
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

8.  Therapeutic concepts in succinate semialdehyde dehydrogenase (SSADH; ALDH5a1) deficiency (gamma-hydroxybutyric aciduria). Hypotheses evolved from 25 years of patient evaluation, studies in Aldh5a1-/- mice and characterization of gamma-hydroxybutyric acid pharmacology.

Authors:  I Knerr; P L Pearl; T Bottiglieri; O Carter Snead; C Jakobs; K M Gibson
Journal:  J Inherit Metab Dis       Date:  2007-04-24       Impact factor: 4.982

9.  Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice.

Authors:  Magali Dumont; Cliona Stack; Ceyhan Elipenahli; Shari Jainuddin; Meri Gerges; Natalia Starkova; Noel Y Calingasan; Lichuan Yang; Davide Tampellini; Anatoly A Starkov; Robin B Chan; Gilbert Di Paolo; Aurora Pujol; M Flint Beal
Journal:  Hum Mol Genet       Date:  2012-08-24       Impact factor: 6.150

10.  Fasting Upregulates PPARalpha Target Genes in Brain and Influences Pituitary Hormone Expression in a PPARalpha Dependent Manner.

Authors:  Bettina König; Christine Rauer; Susann Rosenbaum; Corinna Brandsch; Klaus Eder; Gabriele I Stangl
Journal:  PPAR Res       Date:  2009       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.